170 related articles for article (PubMed ID: 37620821)
1. The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV naïve to antiretroviral therapy.
Fernandes SR; Leite AR; Lino R; Guimarães AR; Pineiro C; Serrão R; Freitas P
BMC Infect Dis; 2023 Aug; 23(1):553. PubMed ID: 37620821
[TBL] [Abstract][Full Text] [Related]
2. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
[TBL] [Abstract][Full Text] [Related]
4. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART).
Bischoff J; Gu W; Schwarze-Zander C; Boesecke C; Wasmuth JC; van Bremen K; Dold L; Rockstroh JK; Trebicka J
EClinicalMedicine; 2021 Oct; 40():101116. PubMed ID: 34522873
[TBL] [Abstract][Full Text] [Related]
5. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain.
Navarro J; Curran A; Raventós B; García J; Suanzes P; Descalzo V; Álvarez P; Espinosa N; Montes ML; Suárez-García I; Amador C; Muga R; Falcó V; Burgos J;
Eur J Intern Med; 2023 Apr; 110():54-61. PubMed ID: 36764905
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.
Yanavich C; Pacheco AG; Cardoso SW; Nunes EP; Chaves U; Freitas G; Santos R; Morata M; Veloso VG; Grinsztejn B; Perazzo H
HIV Med; 2021 Jul; 22(6):445-456. PubMed ID: 33529485
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
9. Switch to a raltegravir-based antiretroviral regimen in people with HIV and non-alcoholic fatty liver disease: A randomized controlled trial.
Shengir M; Lebouche B; Elgretli W; Saeed S; Ramanakumar AV; Giannakis A; De Pokomandy A; Cox J; Costiniuk C; Routy JP; Klein MB; Sebastiani G
HIV Med; 2024 Jan; 25(1):135-142. PubMed ID: 37641534
[TBL] [Abstract][Full Text] [Related]
10. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy.
Mikolasevic I; Domislovic V; Krznaric-Zrnic I; Krznaric Z; Virovic-Jukic L; Stojsavljevic S; Grgurevic I; Milic S; Vukoja I; Puz P; Aralica M; Hauser G
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208576
[No Abstract] [Full Text] [Related]
11. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy.
Perazzo H; Cardoso SW; Yanavich C; Nunes EP; Morata M; Gorni N; da Silva PS; Cardoso C; Almeida C; Luz P; Veloso VG; Grinsztejn B
J Int AIDS Soc; 2018 Nov; 21(11):e25201. PubMed ID: 30394678
[TBL] [Abstract][Full Text] [Related]
13. Indian patients with human immunodeficiency virus infection have high prevalence but mild severity of non-alcoholic fatty liver disease.
De A; Duseja A; Badhala P; Taneja S; Sharma A; Arora S
Diabetes Metab Syndr; 2022 Dec; 16(12):102679. PubMed ID: 36450180
[TBL] [Abstract][Full Text] [Related]
14. Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir.
Calza L; Colangeli V; Borderi M; Bon I; Borioni A; Volpato F; Re MC; Viale P
Infection; 2020 Apr; 48(2):213-221. PubMed ID: 31713814
[TBL] [Abstract][Full Text] [Related]
15. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
16. Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study.
Lao X; Zhang H; Deng M; Li Q; Xiao Q; He L; Ma L; Song A; Liang X; Yu F; Zhao H; Zhang F
BMC Infect Dis; 2024 Jan; 24(1):8. PubMed ID: 38166689
[TBL] [Abstract][Full Text] [Related]
17. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
18. No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults.
Burns JE; Stirrup O; Waters L; Dunn D; Gilson R; Pett SL
HIV Med; 2022 Mar; 23(3):294-300. PubMed ID: 34634168
[TBL] [Abstract][Full Text] [Related]
19. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
